Table 1.
Baseline characteristics of participants.
| N (%) | E-LUAD | HC | NCC | A-LUAD | p-Value |
|---|---|---|---|---|---|
| No. | 21 | 17 | 17 | 25 | |
| Age | 0.3914 | ||||
| Age (IQR) | 60.00 (50.00, 68.00) | 56.00 (47.50, 61.50) | 55.00 (46.00, 61.00) | 59.00 (50.00, 68.00) | |
| Range | 39–83 | 39–69 | 32–78 | 33–76 | |
| Sex | |||||
| Male | 8 (38.10) | 5 (29.41) | 7 (41.18) | 11 (44) | 0.8107 |
| Female | 13 (61.90) | 12 (70.59) | 10 (58.82) | 14 (56) | |
| Smoking status | 0.9395 | ||||
| Never | 13 (61.90) | 12 (70.59) | 12 (70.59) | 16 (64) | |
| Former | 2 (9.52) | 2 (11.76) | 1 (5.88) | 4 (16) | |
| Current | 6 (28.57) | 3 (17.65) | 4 (23.53) | 5 (20) | |
| Tumor history | 0.3033 | ||||
| Yes | 3 (14.29) | 0 | 1 (5.88) | 4 (16) | |
| No | 18 (85.71) | 17 (100) | 16 (94.12) | 21 (84) | |
| Comorbidity | 0.1794 | ||||
| Yes | 5 (23.81) | 0 | 2 (11.76) | 3 (12) | |
| No | 16 (76.19) | 17 (100) | 15 (88.24) | 22 (88) | |
| Cancer stage | |||||
| I | 15 (71.43) | ||||
| II | 6 (28.57) | ||||
| III | 6 (24) | ||||
| IV | 19 (76) | ||||
E-LUAD, early-stage lung adenocarcinoma; HC, healthy control; NCC, non-cancerous lung disease; A-LUAD, advanced lung adenocarcinoma; IQR, interquartile range.